Sudhir Agrawal

Title: Sudhir Agrawal: Innovator in Non-Opioid Pain Therapeutics

Introduction

Sudhir Agrawal is a prominent inventor based in Cambridge, MA, known for his groundbreaking work in the field of pain therapeutics. He has made significant contributions to the development of non-opioid treatments aimed at alleviating pain through innovative approaches.

Latest Patents

Agrawal holds a patent for "Therapeutic compositions for treating pain via multiple targets." This invention provides non-opioid pain therapeutic compositions that include an antisense oligonucleotide (ASO) complementary to an identified target on a NaV channel mRNA. The ASO hybridizes to its target RNA and forms a duplex that recruits RNase H to degrade the RNA, thereby downregulating NaV channel synthesis. This process inhibits the neuron's ability to contribute to the perception of pain. The ASO targets specific identified targets and may be provided as a gapmer that includes a central DNA segment flanked by modified RNA wings. When delivered to dorsal root ganglion (DRG) neurons in vitro, the DRG neurons exhibit a dose-dependent knockdown of NaV1.7, NaV1.8, or NaV1.9.

Career Highlights

Agrawal is associated with Quelltx, Inc., where he continues to advance his research and development efforts in pain management. His innovative work has positioned him as a key figure in the quest for effective non-opioid pain therapies.

Collaborations

He collaborates with notable colleagues, including Owen McManus and David Gerber, who contribute to the research and development initiatives at Quelltx, Inc.

Conclusion

Sudhir Agrawal's contributions to the field of pain therapeutics highlight the importance of innovation in developing non-opioid solutions for pain management. His work continues to pave the way for advancements in therapeutic compositions that can significantly improve patient outcomes.